Products Lipid-lowering agents are mainly sold as tablets and capsules as monopreparations and combination preparations. Some other dosage forms exist, such as granules and injectables. Statins have established themselves as the most important group at present. Structure and properties The chemical structure of lipid-lowering agents is inconsistent. However, within the class, groups with comparable structures … Lipid-Lowering Agents
Alirocumab is an experimental drug for hypercholesterolemia. It is one of the monoclonal antibodies. Alirocumab was introduced in May 2013 at “Pharmacon Meran” by Austrian scientist Manfred Schubert-Zsilavecz. What is alirocumab? Alirocumab is an experimental drug for hypercholesterolemia. Alirocumab functions as an inhibitor (inhibitor) of the human enzyme proprotein convertase subtilisin/kexin type 9 – PCSK9 … Alirocumab: Effects, Uses & Risks
Products The first therapeutic monoclonal antibody was approved in 1986. Muromonab-CD3 (Orthoclone OKT3) binds to the CD3 receptor on T cells and has been used in transplantation medicine. Numerous drugs containing antibodies are now available. A selection of active substances can be found at the end of this article. These are expensive drugs. For example, … Monoclonal Antibodies
Products Alirocumab was approved in the United States and EU in 2015 and in many countries in 2016 as the first agent in the group of PCSK9 inhibitors in the form of a solution for injection (Praluent). Structure and properties Alirocumab is an IgG1 monoclonal antibody with a molecular mass of 146 kDa. Effects Alirocumab … Alirocumab
Products Alirocumab was approved in the United States in 2015 as the first agent in the group of PCSK9 inhibitors in the form of a solution for injection (Praluent). Evolocumab (Repatha) followed as the second agent in the EU, also in 2015. Structure and properties PCSK9 inhibitors to date are monoclonal antibodies that must be … PCSK9 Inhibitors
